Unregulated inflammation shortens human functional longevity

Inflammation Research

Volumn 49, Issue 11, 2000, Pages 561-570

  Brod, S A ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Alzheimer's disease; Atherosclerosis; Autoimmunity; Hayflick phenomenon; Immunosenescence; Inflammation; Proinflammatory cytokines

Indexed keywords

AMYLOID BETA PROTEIN; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 2;

ALZHEIMER DISEASE; ATHEROSCLEROSIS; AUTOIMMUNITY; CARDIOVASCULAR DISEASE; CYTOKINE PRODUCTION; FIBROSIS; HEART INFARCTION; HUMAN; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; LONGEVITY; MULTIPLE SCLEROSIS; REVIEW; RHEUMATOID ARTHRITIS; STROKE; T LYMPHOCYTE ACTIVATION;

ALZHEIMER DISEASE; ARTERIOSCLEROSIS; ARTHRITIS, RHEUMATOID; AUTOIMMUNE DISEASES; AUTOIMMUNITY; CYTOKINES; DIABETES MELLITUS, TYPE 1; HUMANS; INFLAMMATION; LONGEVITY; LYMPHOCYTE ACTIVATION; MULTIPLE SCLEROSIS; T-LYMPHOCYTES;

EID: 0033695682     PISSN: 10233830     EISSN: None     Source Type: Journal    
DOI: 10.1007/s000110050632     Document Type: Review

References (160)

1. Multiple Sclerosis
2. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group
3. Adult and juvenile rheumatoid arthritis: Current epidemiologic concepts
4. Long-term outcome of treating rheumatoid arthritis: Results after 20 years
5. Prediction of long-term mortality in patients with rheumatoid arthritis according to simple questionnaire and joint count measures
6. The mortality of rheumatoid arthritis
7. Current perspectives in Alzheimer's disease
8. Atherosclerosis - An inflammatory disease
9. T cell differentiation and cytokine expression in late life
10. Age-related decline of human interferon alpha and interferon gamma production
11. Effect of age on viral infections: Possible role of interferon
12. T-cell function in aging: Mechanisms of decline
13. Cytokine production pathway in the elderly
14. + CTL activity among elderly persons and the enhancing effect of IL-12
15. Age-related decline in interleukin 2 production in response to influenza vaccine
16. Dihydrotestosterone exerts a depressive influence on the production of interleukin-4 (IL-4), IL-5, and gamma-interferon, but not IL-2 by activated murine T cells
17. Impaired natural killer cell function as a consequence of aging
18. Serum dehydroepiandrosterone (DHEA) and DHEA sulfate are negatively correlated with serum interleukin-6 (IL-6), and DHEA inhibits IL-6 secretion from mononuclear cells in man in vitro: Possible link between endocrinosenescence and immunosenescence
19. Calorie restriction inhibits the age-related dysregulation of the cytokines TNF-alpha and IL-6 in C3B10RF1 mice
20. Altered regulation of IL-6 production with normal aging. Possible linkage to the age-associated decline in dehydroepiandrosterone and its sulfated derivative
21. Increased cytokine production in mononuclear cells of healthy elderly people
22. Lipopolysaccharide-induced lethality and cytokine production in aged mice
23. Cytokine production and lymphocyte subpopulations in aged humans. An assessment during nocturnal sleep
24. Age-associated differences in TNF-alpha and nitric oxide production in endotoxic mice
25. Hypothesis: Multiple sclerosis is a type I interferon deficiency syndrome
26. Multiple Sclerosis
27. Suppressor cell function in multiple sclerosis: Correlation with clinical disease activity
28. Multiple sclerosis as a disease of immune regulation
29. Restricted T cell expression of IL-2/IFN-gamma mRNA in human inflammatory disease
30. Reciprocal allogeneic bone marrow transplantation between NOD mice and diabetes-nonsusceptible mice associated with transfer and prevention of autoimmune diabetes
31. Type I diabetes: A chronic autoimmune disease of human, mouse, and rat
32. What causes diabetes?
33. Antigen presenting cells and the immunogenetics of autoimmune diabetes in NOD mice
34. Transfer of insulin dependent diabetes between HLA-identical siblings by bone marrow transplant
35. T helper cell subsets in insulin-dependent diabetes
36. Analysis of cytokine mRNA expression in syngeneic islet grafts of NOD mice: Interleukin 2 and interferon gamma mRNA expression correlate with graft rejection and interleukin 10 with graft survival
37. Monokine-producing cells predominate in the recruitment phase of NOD insulitis while cells producing Th1-type cytokines characterize the effector phase
38. In vitro modulation of cytokine, cytokine inhibitor, and prostaglandin E release from blood mononuclear cells and synovial fibroblasts by antirheumatic drugs
39. IL-6 is produced by osteoblasts and induces bone resorption
40. Cytokines in chronic inflammatory arthritis II. Granulocyte-macrophage colony-stimulating factor in rheumatoid synovial-effusions
41. Excessive production of IL-6/B cell stimulatory factor-2 in rheumatoid arthritis
42. Constitutive production of interleukin 6/B cell stimulatory factor-2 from inflammatory synovium
43. Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides
44. IL-6 localization in the synovial membrane in rheumatoid arthritis
45. Detection of IL-6 in biological fluids: Synovial fluids and sera
46. Decrease of interleukin 6 during the first 12 months is a prognostic marker for clinical outcome during 36 months treatment with disease-modifying anti-rheumatic drugs
47. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha
48. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis
49. Inhibition of IL-10 expression by IFN-gamma up-regulates transcription of TNF-alpha in human monocytes
50. Interferon-gamma enhances tumor necrosis factor-alpha production by inhibiting early phase interleukin-10 transcription
51. Free radicals and aging
52. Gompertzian mortality originates in the winding-down of the mitotic clock
53. The cell biology of aging
54. Intracellular determinants of cell aging
55. Mortality and immortality at the cellular level. A review
56. Molecular genetic studies of cellular senescence
57. + T cells in centenarians and in long-term T cell cultures: A possible cause for both in vivo and in vitro immunosenescence
58. Human T lymphocytes possess a limited in vitro life span
59. Cytokine secretion of myelin basic protein reactive T cells in patients with multiple sclerosis
60. Replicative senescence of human fibroblast-like cells in culture
61. Autoimmunity, histocompatibility, and aging
62. Aging and immunity
63. Diabetes mellitus, autoimmunity, and ageing
64. Diminished production of type-I interferons and interleukin-2 in patients with multiple sclerosis
65. Alterations in peripheral blood mononuclear cell cytokine production in response to phytohemagglutinin in multiple sclerosis patients
66. PHA-induced interferon in multiple sclerosis: Association between gamma interferon and clinical and genetical variables
67. Molecular pathology of type 1 diabetes
68. GAD65 is recognized by T-cells, but not by antibodies from NOD-mice
69. High T cell responses to the glutamic acid decarboxylase (GAD) isoform 67 reflect a hyperimmune state that precedes the onset of insulin-dependent diabetes
70. CD28/B7 regulation of Th1 and Th2 subsets in the development of autoimmune diabetes
71. T cell proliferative responses to glutamic acid decarboxylase-65 in IDDM are negatively associated with HLA DR3/4
72. Distinct genetic and immunological features in patients with onset of IDDM before and after age 40
73. T-cell reactivity to GAD65 peptide sequences shared with coxsackie virus protein in recent-onset IDDM, post-onset IDDM patients and control subjects
74. Comparison of GAD and ICA512/IA-2 antibodies at and after the onset of IDDM
75. Absence of peripheral blood T cell responses to 'shared epitope' containing peptides in recent onset rheumatoid arthritis
76. Altered T lymphocyte signaling in rheumatoid arthritis
77. Abnormalities of T cell activation in the rheumatoid synovium detected with monoclonal antibodies to CD3
78. Cytokines and the chronic inflammation of rheumatic disease. III. Deficient interleukin-2 production in rheumatoid arthritis is not due to suppressor mechanisms
79. Cytokines in chronic inflammatory arthritis. I. Failure to detect T cell lymphokines (interleukin 2 and interleukin 3) and presence of macrophage colony-stimulating factor (CSF-1) and a novel mast cell growth factor in rheumatoid synovitis
80. Differential diagnosis of Alzheimer's disease
81. Alzheimer's disease: Etiologies, pathophysiology, cognitive reserve, and treatment opportunities
82. Mechanisms of cell death in Alzheimer disease-immunopathology
83. Inflammatory mechanisms in Alzheimer's disease: Implications for therapy
84. Inflammation and Alzheimer's disease: Mechanisms and therapeutic strategies
85. Inflammation and Alzheimer's disease: Relationships between pathogenic mechanisms and clinical expression
86. Importance of immunological and inflammatory processes in the pathogenesis and therapy of Alzheimer's disease
87. Reduced natural killer cell activity in patients with dementia of the Alzheimer type
88. mRNA levels and methylation patterns of the 2-5A synthetase gene in control and Alzheimer's disease (AD) fibroblasts
89. Elevated alpha 1-antichymotrypsin serum levels in a subset of nondemented first-degree relatives of Alzheimer's disease patients
90. Alpha 1-antichymotrypsin as a possible biochemical marker for Alzheimer-type dementia
91. Relationship between serum alpha 1-antichymotrypsin and Alzheimer's disease
92. Serological alpha 1-antichymotrypsin in Down's syndrome and Alzheimer's disease
93. Inflammation, antichymotrypsin, and lipid metabolism: Autogenic etiology of Alzheimer's disease
94. Amyloid-associated proteins alpha 1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer beta-protein into filaments
95. Translation of the Alzheimer amyloid precursor protein mRNA is up-regulated by interleukin-1 through 5'-untranslated region sequences
96. Reciprocal control of inflammatory cytokines, IL-1 and IL-6, and beta-amyloid production in cultures
97. The role of interleukin-6 in certain age-related diseases
98. Interleukin-6 and aging: Blood levels and mononuclear cell production increase with advancing age and in vitro production is modifiable by dietary restriction
99. Inflammatory mechanisms in Alzheimer's disease
100. Inflammatory molecule release by beta-amyloid-treated T98G astrocytoma cells: Role of prostaglandins and modulation by paracetamol
101. Elevated interleukin-6 secretion levels by mononuclear cells of Alzheimer's patients
102. Accumulation of intercellular adhesion molecule-1 in senile plaques in brain tissue of patients with Alzheimer's disease
103. TNFalpha plus IFNgamma induce the production of Alzheimer beta-amyloid peptides and decrease the secretion of APPs
104. Expression of tumor necrosis factor alpha (TNF alpha) and interleukin 6 (IL-6) mRNA in adult human astrocytes: Comparison with adult microglia and fetal astrocytes
105. IL-2 and IL-6 secretion in dementia: Correlation with type and severity of disease
106. Insights into the neurodegenerative process of Alzheimer's disease: A role for mononuclear phagocyte-associated inflammation and neurotoxicity
107. Microglial interleukin-1 alpha expression in brain regions in Alzheimer's disease: Correlation with neuritic plaque distribution
108. Cellular aspects of the inflammatory response in Alzheimer's disease
109. Phagocytic microglia release cytokines and cytotoxins that regulate the survival of astrocytes and neurons in culture
110. IFNβ-1b decreases the migration of T lymphocytes in vitro - Effects on matrix metalloproteinase-9
111. Increased production of gelatinase B (matrix metalloproteinase-9) and interleukin-6 by activated rat microglia in culture
112. Localization of tissue inhibitor of matrix metalloproteinases in Alzheimer's disease and normal brain
113. Oligoclonal bands and blood - Cerebrospinal-fluid barrier dysfunction in a subset of patients with Alzheimer disease: Comparison with vascular dementia, major depression, and multiple sclerosis
114. Neurocytopathic effects of beta-amyloid-stimulated monocytes: A potential mechanism for central nervous system damage in Alzheimer disease
115. Presence of T-cytotoxic suppressor and leucocyte common antigen positive cells in Alzheimer's disease brain tissue
116. The decrease of CD8-positive lymphocytes in Alzheimer's disease
117. Expression of immune system-associated antigens by cells of the human central nervous system: Relationship to the pathology of Alzheimer's disease
118. Immune ageing and Alzheimer's disease
119. Amyloid-beta induces chemokine secretion and monocyte migration across a human blood - Brain barrier model
120. Anti-inflammatory drugs and Alzheimer disease
121. Do nonsteroidal anti-inflammatory drugs decrease the risk for Alzheimer's disease? The Rotterdam Study
122. Nonsteroidal anti-inflammatory drugs in Alzheimer's disease
123. Inverse association of anti-inflammatory treatments and Alzheimer's disease: Initial results of a co-twin control study
124. Delayed onset of Alzheimer's disease with nonsteroidal anti-inflammatory and histamine H2 blocking drugs
125. Risk of Alzheimer's disease and duration of NSAID use
126. The effects of a novel NSAID on chronic neuroinflammation are age dependent
127. A pilot study of prednisone in Alzheimer's disease
128. Clinical trial of indomethacin in Alzheimer's disease
129. Effects of interferon alpha on autocrine growth factor loops in B lymphoproliferative disorders
130. Type 1 interferon as an antiinflammatory agent: Inhibition of lipopolysaccharide-induced interleukin-1 beta and induction of interleukin-1 receptor antagonist
131. A definition of initial, fatty streak, and intermediate lesions of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association
132. Atherosclerosis and inflammation mononuclear cell recruitment and adhesion molecules with reference to the implication of ICAM-1/LFA-1 pathway in atherogenesis
133. Interferon-alpha prevents endotoxin-induced mortality in mice
134. Interferon alpha treatment of relapsing-remitting multiple sclerosis: Long-term study of the correlations between clinical and magnetic resonance imaging results and effects on the immune function
135. Interferon-alpha/beta inhibition of interleukin 12 and interferon-gamma production in vitro and endogenously during viral infection
136. Ingested IFN-alpha has biological effects in humans with relapsing-remitting multiple sclerosis
137. Regional accumulations of T cells, macrophages, and smooth muscle cells in the human atherosclerotic plaque
138. Atherosclerotic lesions in humans. In situ immunophenotypic analysis suggesting an immune mediated response
139. Macrophage and smooth muscle cell proliferation in atherosclerotic lesions of WHHL and comparably hypercholesterolemic fat-fed rabbits
140. Immune mechanisms in atherosclerosis
141. Inflammation in high-grade carotid stenosis: A possible role for macrophages and T cells in plaque destabilization
142. Ligation of CD40 activates interleukin 1beta-converting enzyme (caspase-1) activity in vascular smooth muscle and endothelial cells and promotes elaboration of active interleukin 1beta
143. Regulation of matrix metalloproteinase expression in human vascular smooth muscle cells by T lymphocytes: A role for CD40 signaling in plaque rupture?
144. A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells
145. T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein
146. Human atherosclerotic abdominal aortic aneurysms produce interleukin (IL)-6 and interferon-gamma but not IL-2 and IL-4: The possible role for IL-6 and interferon-gamma in vascular inflammation
147. Activation of monocytes, T-lymphocytes and plasma inflammatory markers in angina patients
148. Expression of intercellular adhesion molecule-1 on rat vascular smooth muscle cells by pro-inflammatory cytokines
149. Atherosclerosis and inflammation mononuclear cell recruitment and adhesion molecules with reference to the implication of ICAM-1/LFA-1 pathway in atherogenesis
150. Jr Shear stress selectively upregulates intercellular adhesion molecule-1 expression in cultured human vascular endothelial cells
151. Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men
152. Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: The Atherosclerosis Risk In Communities (ARIC) study
153. Expression of inflammatory mediators and adhesion molecules in human atherosclerotic plaque
154. Increased endothelial expression of intercellular adhesion molecule-1 in symptomatic versus asymptomatic human carotid atherosclerotic plaque
155. Circulating cell adhesion molecules are correlated with ultrasound-based assessment of carotid atherosclerosis
156. Cytokine expression in advanced human atherosclerotic plaques: Dominance of pro-inflammatory (Th1) and macrophage-stimulating cytokines
157. Expression of interleukin-10 in advanced human atherosclerotic plaques: Relation to inducible nitric oxide synthase expression and cell death
158. Protective role of interleukin-10 in atherosclerosis
159. Arterial and venular endothelial cell costimulation of cytokine secretion by human T cell clones